|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Bolus infusion  3 mcg | Bolus infusion  \*0.3 mcg | Subcutaneous  injection  2 mcg/kg/day | Continuous  intravenous infusion  2 mcg/kg/day | Subcutaneous  ALT-803T (2)  10 mcg/kg |
| Cmax pg/kg | 43,900 | 1,260 | 1,638 | 5,662 | 8,000 |
| pg/mL AUC | 43,400 | 1,960 |  | 321,747 |  |
| Maximum fold increase  in IL-6  concentration pg/mL | 30 | NA | 17 | 10 |  |
| MTD | 0.3 mcg/kg | 0.3 mcg/kg | 2 mcg/kg | 2 mcg/kg |  |
| Maximum fold increase in number  of circulating NK cells | ≥10 | 3 | 10.8 | 38 | 8 |

\*MTD or expansion cohort

**Supplementary Table 2: Comparison of Pharmacokinetics with Different Dosing Strategies**